权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a novel cell-based immune therapy using Nanoparticles and natural IgM-producing phagocytic B cells

使用纳米颗粒和天然产生 IgM 的吞噬 B 细胞开发新型细胞免疫疗法

基本信息

批准号：
9262189
负责人：
Xuemei Zhong
金额：
$ 18.68万
依托单位：
BOSTON MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-04-15 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9262189
关键词：
Address Adoptive Immunotherapy Adoptive Transfer Advanced Malignant Neoplasm Age Animal Model Anti-Inflammatory Agents Anti-inflammatory Antibodies Antigen Presentation Apoptotic Autoantigens B-Lymphocytes Blood Banks Body cavities CD19 gene Cancer Patient Cancer Remission Cancerous Cell Count Cell Death Cell physiology Cells Code Combined Modality Therapy Development Diphtheria Toxin Drug resistance Environment Evolution Future Germ Cells Goals Human Immune response Immune system Immunofluorescence Immunologic Immunoglobulin M Immunologic Monitoring Immunologic Surveillance Immunotherapy In Vitro Incubated Individual Infiltration Inflammation Injection of therapeutic agent Interleukin-10 Lecithin Lipids Liposomes Maintenance Malignant Neoplasms Mediating Melanoma Cell Methods Modeling Monitor Mus Neoplasm Metastasis Normal Cell Patients Peritoneal Phagocytes Phagocytosis Phospholipids Play Primary Neoplasm Process Production Regulation Reporting Research Resistance development Role Second Primary Cancers Signal Pathway Soldier System Testing Time Tissues Tumor Antigens Tumor Cell Line anticancer research base body cavity cancer cell cancer heterogeneity cancer immunotherapy cancer prevention cancer therapy carcinogenesis cell growth cell motility chemokine chemotherapy clinical application combat controlled release cytokine design drug development experimental study in vivo knockin animal melanoma mouse model nanoparticle neoplastic cell novel novel therapeutics prevent protein expression public health relevance self-renewal success tumor tumor heterogeneity weapons

项目摘要

DESCRIPTION (provided by applicant): Tumor heterogeneity and drug-resistance are the leading challenges for cancer immunotherapy. Our goal is to explore the immune surveillance mechanism to develop a broad tumor-recognizing immunotherapy that is self-sustaining and adaptive to tumor evolution. PRELIMINARY RESULTS: We have discovered natural IgM-producing phagocytic B cells (NIMPAB). In mice, L2pB1 cells are the major NIMPAB cells that produce natural IgM antibodies, which are known for their broad-spectrum cancer recognition. Our research has shown that L2pB1 cells can inhibit tumor cell growth and phagocytose apoptotic tumor cells. L2pB1 cells are also the predominant B cells that constitutively express the anti-inflammatory cytokine IL-10 and inducibly express the highest level of IL-10 among all B cells. HYPOTHESIS: We hypothesize that L2pB1 cells have a unique repertoire of broad cancer-recognizing natural IgM antibodies as well as multiple anti-cancer functions. L2pB1 cells might play fundamental roles in cancer immune surveillance through cancer cell recognition, inhibition, antigen presentation and clearance by phagocytosis with tight control of inflammation that prevents tissue damage. Boosting L2pB1 cell number and functions may induce cancer remission and prevent secondary cancer development. APPROACH: To test this, we propose to utilize a combined therapy model using (1) intratumoral injection of L2pB1 cell-attracting chemokines packaged in nanoparticles for controlled release. (2) Adoptive transfer of PtC-liposome expanded L2pB1 cells from self or healthy donors. To facilitate these experiments, we generated a novel knock-in animal model, which allows us to track, monitor and quantify L2pB1 cells in vivo. It also allows inducible depletion of L2pB1 cells at any time. We will inoculate 3 different tumor cell lines in these mice and evaluate tumor inhibition with this combined treatment. NOVELTY: Current immunotherapy strategies utilize the "weapons" (molecules) and "soldiers" (cells). Our proposed cancer therapy introduces the "commander" of our immune surveillance system to establish a sustainable "command center" with more efficient regulation and adaptation to the heterogeneity of tumors. FUTURE CLINICAL APPLICATION: If we achieve the goals of our study, we would be able to cryopreserve patients' NIMPAB cells before chemotherapy. Alternatively, if some patients are deficient in NIMPAB cells, they could receive a NIMPAB transfer from healthy donors. As NIMPAB can self-renew, a blood bank of NIMPAB can be established from healthy donors or any individual at a young age to use in case the cells are needed when the respective donor becomes older. SIGNIFICANCE: The proposed novel therapy model will significantly advance the cancer immunotherapy field by providing a potential self-renewable therapy for both cancer treatment and cancer prevention. This new therapy addresses the current challenges of lack of sustainability and adaptation to cancer heterogeneity, and will provide a giant leap forward in the cancer immunotherapy field.